东亚药业股价跌5.04%，诺安基金旗下1只基金位居十大流通股东，持有81.17万股浮亏损失84.42万元

Group 1 - East Asia Pharmaceutical's stock price fell by 5.04% on November 21, closing at 19.58 CNY per share, with a trading volume of 14.90 million CNY and a turnover rate of 0.66%, resulting in a total market capitalization of 2.246 billion CNY [1] - The company's stock has experienced a continuous decline over three days, with a cumulative drop of 3.87% during this period [1] - East Asia Pharmaceutical, established on February 6, 1998, and listed on November 25, 2020, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] Group 2 - The main revenue composition of East Asia Pharmaceutical includes: β-lactam antibiotics (44.84%), anticholinergic and synthetic antispasmodic drugs (23.92%), quinolone antibiotics (12.86%), antifungal drugs for skin use (8.87%), other products (5.05%), and additional items (4.46%) [1] - Among the top ten circulating shareholders, a fund under Nuoan Fund, Nuoan Multi-Strategy Mixed A (320016), entered the list in the third quarter, holding 811,700 shares, which accounts for 0.72% of the circulating shares [2] - The estimated floating loss for Nuoan Multi-Strategy Mixed A today is approximately 844,200 CNY, with a floating loss of 673,700 CNY during the three-day decline [2] Group 3 - The fund manager of Nuoan Multi-Strategy Mixed A is Kong Xianzheng, who has been in the position for 4 years and 361 days, managing a total fund size of 5.608 billion CNY [3] - During his tenure, the best fund return was 95.2%, while the worst return was -16.74% [3]